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AbstrACt
Objectives To undertake a meta-ethnographic synthesis 
of findings from primary studies reporting qualitative data 
that have explored participant-reported factors influencing 
non-retention within a clinical trial context.
Design A systematic search and meta-ethnography was 
conducted for published papers (from 1946 to July 2018) 
that contained qualitative data from trial non-retainers.
Participants We identified 11 studies reporting qualitative 
data from 13 trials. The studies were undertaken between 
2008 and 2018. Each study included between 3 and 40 
people who had dropped out from a trial, with findings 
from 168 people in total reported across the papers.
results Emergent from our synthesis was the 
significance of trial non-retainers’ perceptions around the 
personal ‘fit’ of key aspects of the trial with their personal 
beliefs, preferences, capabilities or life circumstances. 
These related to their own health state; preferences for 
receiving trial ‘care’; individual capabilities; beliefs about 
or experiences of trial medication and considerations 
whether trial participation could be accommodated into 
their broader lives. All these factors raise important issues 
around the extent to which initial decisions to participate 
were fully informed.
Conclusions To improve retention in clinical trials, 
researchers should work to reduce the burden on trial 
participants both through the design of the intervention 
itself as well as through simplified data collection 
processes. Providing more detail on the nature of the trial 
interventions and what can be expected by ‘participation’ 
at the consenting stage may prove helpful in order to 
manage expectations. 
IntrODuCtIOn 
Randomised controlled trials (RCTs) are 
integral for evidenced-based clinical deci-
sion making. Within the context of clinical 
trials, the focus of much methodological 
research in recent years has been on issues 
specifically relating to trial recruitment, 
including significant investigation into how 
to increase the numbers of prospective partic-
ipants recruited.1 2 A key focus of much of 
this research has been on trial participants’ 
perspectives and experiences particularly 
around why they do or do not choose to 
consent to participate in clinical trials.3–7 
While issues relating to trial recruitment are 
undoubtedly important, issues around reten-
tion (ie, ensuring that trial participants remain 
in the trial to provide primary outcome data) 
have not received equal scrutiny in the litera-
ture despite being arguably just as important 
for trials in terms of ensuring that research 
questions are adequately answered.2
Trial retention was recently identified in 
the top three priorities for methodological 
research by UK trialists.8 Most trials experi-
ence the issue of missing data often referred 
to as a ‘loss to follow-up’, ‘attrition’ or ‘drop 
out’ and this can bias the findings of a trial. 
Some recent quantitative surveys have iden-
tified participant characteristics (eg, age, 
gender, physical or mental health) or trial 
processes (eg, study duration or length and 
strengths and limitations of this study
 ► Trial retention has recently been identified as one of 
the top three priorities for methodological research 
by UK trialists.
 ► Within the context of clinical trials, issues around re-
tention have not received equal scrutiny compared 
with methodological questions about trial recruit-
ment despite being arguably just as important for 
trial validity.
 ► Understanding the complex reasons why trial par-
ticipants leave a trial after initially consenting is im-
portant if trialists are to be able to design effective 
intervention strategies to address the problem.
 ► To our knowledge, this is the first synthesis of key 
qualitative findings from studies exploring partici-
pants’ perspectives of trial non-retention, which pro-
vides learning across their collective contributions.
 ► Our synthesis only included 11 eligible papers re-
porting findings across 13 trials, 5 of which were set 
within a mental health context and all of which were 
conducted in high-income countries.  This could 
have issues for the transferability of findings.
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relevance of outcome measures) as being potential 
predictors of trial retention.9–11 However, these studies 
are small in size, often limited to a particular clinical 
context, and the items included in the surveys are often 
identified by researchers rather than asking participants 
what items should be included. In addition, they lack any 
in-depth exploration of the relevant issues affecting why 
participants withdraw, as reported by participants.
Understanding the complex reasons why trial partici-
pants leave a trial (either actively (eg, by requesting no 
further follow-up or purposefully not returning data) 
or passively (eg, forgetting to return a questionnaire or 
attend a clinic visit)) after initially consenting to partici-
pation is important, especially if those reasons are modifi-
able. This understanding of participant perspectives then 
becomes crucial if trialists are to be able to design effec-
tive intervention strategies to address the problem.
The approach of conducting in-depth qualitative 
research within the context of clinical trials is considered 
particularly useful for improving the evidence base for 
how trialists conduct them.12 Indeed, this approach has 
been used widely to explore perspectives on trial recruit-
ment both in terms of primary qualitative studies and 
secondary syntheses. To our knowledge, this is the first 
synthesis of key findings from studies exploring partici-
pants’ perspectives of trial non-retention, which provides 
learning across their collective contributions. Our aim 
was to undertake a meta-ethnographic synthesis of find-
ings from such studies and our specific research question 
was ‘what influences non-retention in clinical trials’?
MethODs
A systematic literature search and meta-ethnography 
was conducted (see online S1 ENTREQ Checklist). This 
meta-ethnography was undertaken in two parts. Our orig-
inal systematic search and synthesis was undertaken in 
August 2016. To integrate potentially more recent rele-
vant research, we undertook an update in July 2018.
Meta-ethnography essentially involves an ‘interpretive 
and inductive’ approach to synthesising studies.13 14 Essen-
tially meta-ethnography involves the process of ‘trans-
lating’ the findings of individual qualitative studies so 
that they can be considered in relation to one another 
with the aim of identifying and building new conceptual 
knowledge on a particular topic.13 14 The process of ‘trans-
lating’ findings across studies can be either ‘reciprocal’ or 
‘refutational’ depending on how individual studies relate 
to each other.13
searching and identification of relevant studies
A systematic search was conducted for published papers 
that contained qualitative data about trial participants’ 
reasons for not completing some or all of the processes 
involved in a clinical trial after initially consenting to take 
part (which we describe as constituting non-retention). 
Search strategies were informed by previous studies12 and 
are provided in online supplementary appendix 1. Seven 
electronic databases were searched by an information 
specialist: Embase, Ovid MEDLINE, PsycINFO, Cochrane 
Central Register of Controlled Trials, The Social Sciences 
Citation Index, Cumulative Index of Nursing & Allied 
Health Literature and Applied Social Sciences Index and 
Abstracts and covered papers published from 1946 to 
August 2016 (first search) and from August 2016 to July 
2018 (updated search). Google Scholar and bibliogra-
phies of identified publications were also searched manu-
ally for additional potentially eligible papers.
For both searches, one author screened all titles and 
abstracts (RN for original search; ZCS for update) with 
a second author (KG) screening a random 10% sample. 
Eligible studies included those that used qualitative 
methods and contained qualitative data exploring any 
aspect of non-retention from the perspective of patient 
participants (recognising that non-retention might cover 
activities such as cessation of or withdrawal from the 
intervention(s), non-attendance at clinic visits, through 
to non-response to some or all follow-up questionnaires, 
etc).
Analysis and synthesis
In order to collate and synthesise the available primary 
research, the seven steps of meta-ethnography as listed in 
online supplementary S1 box were followed. In summary, 
the three authors (ZCS, RN, KG) each read and systemati-
cally extracted data from the included papers, shared notes 
and discussed study findings and interpretations during a 
series of group meetings. The papers were initially organ-
ised in chronological order (but as inductive analysis 
progressed papers were grouped according to emerging 
themes) and we focused on the findings, concepts and 
themes used by the papers’ authors generating a list of key 
categories. We used a standard form which summarised 
the main themes, information regarding methods and 
any other important information relating to the context 
of the research within each study (some of these data are 
illustrated in online supplementary S1 table). Although 
we initially organised papers chronologically in this table, 
we used it to facilitate a series of further group discus-
sions around emerging issues (see online supplementary 
S2 table). As inductive analysis progressed, we grouped 
and discussed our data according to the five key emerging 
themes (see online supplementary S3 table). In line with 
the process of undertaking a meta-ethnography, primary 
data or ‘first-order constructs’ (quotations from study 
participants who had not completed any or some of the 
various trial processes) and authors’ interpretations of 
these data (‘second-order constructs’) were extracted, 
compared and contrasted between studies (enabling us 
to produce a ‘reciprocal translation’), and organised into 
themes to facilitate the development of new insights or a 
‘line of argument’.13
study quality
One author (ZCS) undertook a quality assessment of each 
of the papers included in the synthesis. This was based on 
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the Critical Appraisal Skills Programme (CASP) criteria,15 
which was used to appraise the identified primary studies 
and consider their inclusion into the synthesis (see online 
supplementary S1 CASP checklist). Questions developed 
by the CASP have been used previously for appraising the 
quality of studies for inclusion in meta-ethnography.16–20
Patient and public involvement
This research was done without patient involvement. 
Patients were not invited to comment on the study 
design and were not consulted to develop patient rele-
vant outcomes or interpret the results. Patients were not 
invited to contribute to the writing or editing of this docu-
ment for readability or accuracy.
results 
Description of studies
The database search produced 1431 abstracts for the 
initial search and 697 abstracts for the update (see online 
supplementary S1 Figure and S2 Figure for details). We 
only included studies that provided data about reasons 
for non-retention from the included study participants 
and/or in the authors’ reflections. In all, 11 papers met 
our inclusion criteria (8 were identified from the initial 
search and 3 from the update). The focus and key study 
characteristics for the 11 included papers are outlined 
in online supplementary S1 table. The identified papers 
were conducted in seven countries (the UK, the USA, 
Australia, Sweden, The Netherlands, Denmark and 
Spain) and discussed non-retention in 13 separate trials. 
Six of the papers focused solely on reasons for non-re-
tention,21–26 with the remaining five also considering 
reasons for consenting,27 non-consenting28 29 and reten-
tion.30 31 The findings in this synthesis relate to the data 
from non-retainers only. Each study included between 3 
and 40 people who had dropped out from a trial, with find-
ings from 168 people in total reported across the papers. 
As can be seen from online supplementary S1 table, the 
setting of the trials in which the qualitative research was 
embedded included a range of clinical contexts such as: 
mental health problems21 24 26; mental health problems 
and cancer23; problem drinking22 25; type 1 diabetes30; 
diabetes, chronic obstructive pulmonary disease (COPD), 
heart failure or social care needs28; severe ankle sprains31; 
asymptomatic atherosclerosis29; neurodevelopment disor-
ders27 and osteopenia.27 As expected, the clinical context 
differed as did the interventions under investigation and 
included: telehealth equipment or telecare devices28; 
web-based psycho-educational/cognitive therapy-based 
support tools21 22 24 26; antidepressant medication and/
or cognitive behavioural therapy23; exercise25 30; various 
mechanical ankle supports31; aspirin29; melatonin27 
and bisphosphonate risedronate or vitamin D analogue 
1-alpha-hydroxycholecalciferol.27
Findings were presented from trial non-retainers both 
before outcome data had been collected (eg, those who 
withdrew from the intervention) and/or during the 
follow-up when outcome data were being collected—in 
other words, papers included a mix in terms of non-reten-
tion behaviour (see online supplementary S1 table for a 
summary of non-retention behaviour, that is, non-adher-
ence to intervention, non-return of questionnaires). For 
example, eight studies reported aspects related to non-ad-
herence to trial intervention: three of these reported 
cessation of trial medication23 27 29 (for both trials); five 
reported cessation of treatment therapy sessions21–24 26; 
one reported cessation of use of telehealth equipment or 
telehealth devices28 and another reported non-comple-
tion of study workbooks.21 Two studies reported non-re-
turn of follow-up questionnaires.22 31 For two studies, 
non-retention behaviour was unspecified.25 30 Three 
of the 11 studies appeared to have included only the 
views of those who had dropped out of the active inter-
vention arms of the trial.23 24 28 For four studies, it was 
unclear whether data were from intervention or control 
groups26 27 29 31 and only four studies specifically stated 
that they included views of both those in the intervention 
and control groups.21 22 25 30
Nine of the 11 studies used semi-structured interviews 
to collect data from people who had withdrawn from the 
main trial21 23–28 30 31; one used a combination of focus 
groups and interviews29 and another distributed a ques-
tionnaire that contained various open-ended response 
options23 (NB: only the qualitative data are reported and 
referred to in this paper). Although some papers provided 
gender, age and/or demographic details for participants 
taking part in the trial in question, as can be seen from 
online supplementary S1 table, this information was less 
comprehensive for those who had dropped out of the 
trial. Where participant characteristic information was 
provided in the original studies, we have included this at 
the end of the quotes presented to illustrate findings.
Key themes from the synthesis
Our grouping of first-order and second-order constructs 
across the 8 initially identified papers resulted in 14 
subthemes. During the process of translating themes from 
each of the individual studies (ie, comparing and contrasting 
across studies), these subthemes were then grouped and 
categorised into five broad key themes which characterised 
the main considerations and features that appeared to influ-
ence non-retention in the trials under investigation (see 
online supplementary S2 table). For the three subsequently 
identified papers, we repeated the various stages of meta-eth-
nography—in essence comparing for ‘fit’ and checking for 
any additional themes.32 33 For the update, we attempted 
to follow the ‘extend and renovate the house’ approach,33 
which involves examining the newly included studies to estab-
lish whether they add new concepts or contribute to existing 
ones. During this process, we were confident that concepts 
identified in the later three papers supported and comple-
mented our originally identified five key themes (from the 
original eight studies) with no new concepts emerging.
These themes were: (1) perceptions of current health 
state in relation to specific aspects of the trial; (2) the ‘fit’ of 
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aspects of the trial with individual preferences for care and 
support; (3) the compatibility of aspects of trial processes 
with individual capabilities; (4) concerns about or experi-
ences of trial medication and (5) considerations around the 
extent to which trial participation could be appropriately 
accommodated into individuals’ broader lives.
As these theme labels suggest, within them they accom-
modate a spectrum of views or experiences.
The five broad key themes identified as influencing 
participants’ non-retention in clinical trials are illustrated 
with example data in online supplementary S2 table. In 
online supplementary S2 table, primary study participant 
quotes illustrating first-order constructs are displayed in 
italics, and primary study author interpretations illus-
trating second-order constructs are presented in bold 
text. In the rest of this paper, primary study participant 
quotes are displayed in italics.
Influences on participant non-retention in clinical trials: a line 
of argument
Expressed below is our ‘line of argument’, which is 
organised into themes to facilitate the development of 
cumulative insights (online supplementary S3 figure 
conceptually illustrates the line of argument developed 
from the synthesis). These themes appear to be weighed 
up during the participant’s involvement in the trial and 
set alongside the complex inter-relationship between self 
and trial processes/procedures and ultimately impact on 
their retention in the trial. Overall, our argument empha-
sises the significance of trial participants’ perceptions 
around the ‘fit’ of key aspects of the trial (intervention 
and trial processes) with their personal beliefs, prefer-
ences, capabilities or life circumstances. These factors 
(which were not necessarily mutually exclusive) related to 
beliefs about their own health state, preferences for how 
they wanted to receive care, their individual capabilities, 
beliefs about or experiences of trial medication and also 
considerations around the extent to which trial participa-
tion could be appropriately accommodated (or not) into 
their broader lives. All of these were set against the overall 
backdrop of the balance between their sense of self and 
the trial processes and procedures—this providing the 
overarching explanation for the influence on reten-
tion in trials. Implicit within several of these identified 
factors is the suggestion that there may have been defi-
cits within the initial trial consenting process which led to 
participants (who subsequently withdrew) not being fully 
informed or at least not realising what the trial expected 
of them and what they could expect of the trial. These 
findings are discussed in more detail below and arranged 
across five key themes.
Perceptions of current health state in relation to specific aspects of 
the trial
This theme describes how aspects of the trial might not 
be right for people as individuals. For example, across 8 
of the 11 studies a key influence on decisions to discon-
tinue trial participation appeared to relate to perceptions 
of either being ‘too well’ to warrant further engagement 
with the trial21–23 25 28 29 31 or struggling with the compati-
bility of aspects of the trial, particularly the interventions 
or ways outcomes were assessed, with their personal sense 
of self.21 22 25 28–30 Conversely, other participants described 
periods of feeling too unwell to be able to engage appro-
priately in trial processes. 
Being too well to engage further with trial processes
Some participants cited a belief that they had suitably 
recovered part way through a particular trial as a reason 
for discontinuing trial medication and/or problem 
solving treatment exercises.21–23 25 For some, this was also 
linked to not wanting to be reminded about health issues 
that they considered to be over:
I just don’t want to be reminded of the alcohol thing, because 
I actually think it’s over25 (female, 30–68 years, alcohol 
use disorder)
Things really improved for me…I just felt really good and 
didn’t really feel like I had that much to offer in regard to 
finding out more about it21 (female, 30–39 years, bipolar 
disorder, control group)
I have been sufficiently helped22 (no gender/age details, 
problem drinker, intervention group)
Participants also cited recovery as a reason for not 
completing and returning all the required follow-up 
outcome assessment questionnaires,28 (severe ankle 
sprains) perhaps highlighting here the importance at 
the consenting stage of making sure participants are 
fully informed about the value of sustained engage-
ment throughout the duration of the trial (even if they 
feel they are no longer personally benefiting from that 
engagement). 
Lack of compatibility with personal sense of self
Sometimes reasoning around trial withdrawal related 
to participants’ struggle to accommodate aspects of the 
trial with their personal sense of self at the time,25 28 29 
suggesting that the intervention challenged their sense 
of self somehow. Again perhaps indicating the impor-
tance for initial trial recruitment consultations to include 
adequate discussions about the nature of the study inter-
vention and also what will be expected of participants in 
terms of engagement with them. For example, a belief 
that they could self-manage or cope well enough without 
the need to engage with the trial support intervention28 
(self-care intervention to facilitate support for self-man-
agement in ageing populations); a belief that they were 
too overweight and unfit to participate in a group exer-
cise intervention25 (exercise intervention for people with 
alcohol use disorder); a belief that they had adequately 
managed their condition thus far without the need for 
any medication29 (aspirin for asymptomatic atheroscle-
rosis) and also non-acceptance of a diagnosis among 
those newly diagnosed21 30 (with bipolar disorder; with 
type 1 diabetes) as a reason for not relating to (or seeing 
any value in) the study interventions:
 o
n
 11 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-021959 on 3 June 2019. Downloaded from 
5Skea ZC, et al. BMJ Open 2019;9:e021959. doi:10.1136/bmjopen-2018-021959
Open access
(Discussing the need to keep active rather than mon-
itoring his health indoors using telehealth equip-
ment) You’ve got (to have) the will power…if you can’t 
do it I am finished. If I wouldn’t have that I’d be, I’d be 
stuck inside here you know, and looking through the win-
dow like…I throw myself in the garden and everything. 
Everything I do I’m working on, I cook myself dinners and 
everything.28 (Male, 85 years, COPD)
I think if it had been medication that I needed to take, I 
would have taken it29 (male, 72 years, stopped taking 
aspirin medication)
If you’re taking a lot, it knocks the hell out of your stom-
ach…Given the choice, I’d rather not take medication full 
stop29 (male, 55 years, stopped taking trial medication 
for asymptomatic atherosclerosis)
I wasn’t ready to accept the illness. At that stage after di-
agnosis I wasn’t willing to change my life according to the 
programme.21 (Male, 18–29 years, bipolar disorder, 
control group)
Don’t think it kind of really sank in as to what I’d been 
diagnosed with … It had kind of hit me and I wasn’t really 
dealing with having it … 30 (female, 19–55 years, type 
1 diabetes)
If trial participants believed that the trial did not fit 
with their personal sense of self, this was also linked to an 
emotional response. For example, feelings of guilt and 
shame that they were too overweight and unfit to partic-
ipate in a group exercise intervention25 (exercise inter-
vention for people with alcohol use disorder).
Being ‘too ill’ to be able to engage appropriately with trial 
interventions
Conversely, within all of the papers focussing on inter-
ventions for mental health conditions, and in one paper 
focussing on people newly diagnosed with type 1 diabetes, 
participants described being ‘too ill’ to be able to engage 
appropriately in trial processes.21 23 24 26 30 Reasons 
discussed in this context related to feeling either too 
fragile, depressed, too manic or too emotional/stressed 
at certain times to be able to complete the required inter-
vention tasks (eg, e-health intervention and associated 
workbook activities; cognitive behavioural therapy; taking 
blood samples) and also a concern that engagement with 
the intervention could act as a ‘trigger’ in terms of exac-
erbating anxiety symptoms:
I was feeling that the therapy wasn't going to help me with 
my problems. I thought it could lead me to be even more anx-
ious and that it wasn't going to be beneficial for me. So, I 
felt that I was going to waste my time if I continued26 (no 
gender details, 21–59 years, people with a range of se-
rious mental health problems)
I did not cope with the exercises. I did them at the start but it 
gradually became more difficult to complete them….particu-
larly the breathing exercises. I got a bit dizzy and it increased 
my feelings of anxiety24 (no gender or age details, gen-
eralised anxiety disorder)
The biggest problem I have with my bipolar disorder is con-
sistency; when I’m down I can’t even brush my teeth or get 
up in the morning. So doing an education programme with 
workbooks was beyond me21 (female, 18–29 years, bipolar 
disorder, Bipolar Education Program group)
I often go walking when having highs because I have to keep 
moving, so I didn’t want to sit at a computer21 (male, 40–
49 years, bipolar disorder, bipolar education program 
(BEP) + informed supporter (IS) group)
As with the earlier subthemes in this section, 
emotional influences were also woven through this 
perception of being ‘too ill’ to engage with the trial. 
One study pointed to the ‘emotional impact of the 
cancer diagnosis’ as being an influential factor linked 
to participant drop out.23
The ‘fit’ of aspects of the trial with individual preferences for care 
and support
Across 8 of the 11 studies another important influence 
in decisions to discontinue trial participation appeared 
to relate to the fit of aspects of the intervention with 
preferences for how participants wanted to receive care 
and support,21–26 28 31 implicitly suggesting that the initial 
trial consenting process may have been suboptimal in key 
ways. Participants in these trials discussed how aspects of 
the design of the interventions were not individualised 
or tailored enough to be helpful and others commented 
on interventions being either too technical, too physically 
demanding, too intensive or conversely too basic:
I needed a therapy that could better address what I felt. It 
didn't give me a specific answer to my worries.26 (No gen-
der details, 21–59 years, people with a range of seri-
ous mental health problems)
I would have liked to have more of a personal contact, it 
became a little distant everything, to do on the internet, be-
cause it is so heavy stuff, it’s nice to meet a real person when 
you’re working with heavy things like this24 (no gender or 
age details, generalised anxiety disorder)
I wanted something more about me specifically, as opposed to 
talking about general issues21 (male, 40–49 years, bipolar 
disorder, BEP group)
 The information in the modules was too general and too 
limited21 (male, 18–29 years, bipolar disorder, BEP 
group)
Some other participants simply indicated that they 
had been unhappy or dissatisfied or ‘not comfort-
able’ with the treatment they had received, although 
specific reasons were not provided within the included 
studies.22 23 31
The compatibility of aspects of trial processes with individual 
capabilities
Across 3 of the 11 studies,23 24 31 the extent to which 
aspects of the interventions were deemed to be appro-
priately ‘pitched’ at the individual emerged as being of 
importance. For example, participants cited attention 
 o
n
 11 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-021959 on 3 June 2019. Downloaded from 
6 Skea ZC, et al. BMJ Open 2019;9:e021959. doi:10.1136/bmjopen-2018-021959
Open access 
problems and limited reading and writing skills as a 
reason for withdrawing from internet delivered cognitive 
behavioural therapy24 or as a reason for non-response to 
follow-up questionnaires,31 with participants in one of 
these studies stating that they felt unintelligent because 
of their inability to understand.24 Communication and 
cultural issues were also cited as reasons for the discontin-
uation of problem solving treatments,23 suggesting that 
these issues would benefit from greater consideration 
and discussion at the consenting stage:
I thought that it was too much to read, and I cannot read 
anything at all that I need to remember or learn. It goes in 
here and out there (pointing at the ears)24 (no gender or 
age details, generalised anxiety disorder)
Concerns about or experiences of the trial medication
Across two of the eight studies which were set within trials 
testing drug interventions27 29 , concerns about the study 
medication were cited as reasons for discontinuing with 
trial participation. These included concerns that the trial 
drug(s) were not properly tested/licensed,27 concerns 
that the trial medication could negatively interact with 
other prescribed medication,29 through to citing a dislike 
of taking too much medication29 or that the trial medica-
tion tasted offensive.27 Constructs within this key theme 
again suggest potential issues with the informed consent 
process and highlight the importance of discussions about 
the purpose of any trial, the nature of trial medications 
and also the implication for participation of having certain 
comorbidities, linking back into the complex inter-rela-
tionship between self and trial processes/procedures:
It just scared me when it said not to be given to children 
under 20…I didn’t understand they weren’t licensed for 
children…and that’s what I thought it was, just to see if 
it worked, not to actually like so then it could be licensed27 
(mother of child in trial for young people aged 
4–18 years with rheumatic diseases)
again I found that I had stomach problems with the tab-
let so I assumed that it must be the aspirin…29 (female, 
63 years, stopped taking trial medication for asymp-
tomatic atherosclerosis)
…and they discovered I had heart fibrillation…After that 
I’d to go on warfarin you see, so that’s why I had to drop out 
because warfarin and aspirin just don’t agree29 (female, 
77 years, stopped taking trial medication for asymp-
tomatic atherosclerosis)
I didn’t think I really wanted to go on at the start but mum 
and dad persuaded me to. And so…when I was getting 
really fed up I just said ‘No I don’t want to’ because I didn’t 
like the taste (of the medicine)27 (POP trial; young person 
11–14 years)
Considerations around the extent to which trial participation could 
be appropriately accommodated into their broader lives
Aside from issues relating to beliefs about current health 
state, individual capabilities, preferences for care and 
concerns about side effects, participants also discussed 
how decisions to discontinue with trial participation 
related to other life ‘events’ that tended to take priority 
over or made it hard for them to engage fully with the 
various demands of the trial.21–26 30 31 These factors 
appeared less directly related to the nature of the trial 
interventions themselves and more about the challenges 
of life in general (with one study31 suggesting that these 
people could be classed more as ‘happy’ rather than 
‘unhappy’ non-responders, in the sense that non-reten-
tion may be related to aspects out with the trial itself). 
Reasoning here involved trading off trial participation 
with competing priorities and ranged from events such 
as work or family, moving to another country, exams, 
pregnancies, postal strikes, etc and more generally simply 
daily routines that got in the way. Within one study,25 the 
importance of existing social networks was highlighted, 
with some participants citing a lack of support from family 
members as a reason for discontinuing trial participation. 
Within this theme participants also sometimes cited ‘lazi-
ness’ or ‘forgetfulness’ as reasons for why they had either 
not completed trial interventions or had not responded 
to follow-up questionnaires with some apparently being 
unaware that they were being considered as ‘drop outs’ 
by study researchers:
(Discussing cessation of therapy sessions/non-com-
pletion of study workbooks) I didn’t have the time, and 
with everything else, it wasn’t a priority21 (female, 18–
29 years, bipolar disorder, control group)
(describing why they did not return a follow-up ques-
tionnaire) Do you know what…laziness I’m just gonna 
put it down to that
Researcher: OK and em it wasn’t because you were dis-
gruntled about part of the project?
Definitely not no31 (no gender/age details given, severe 
ankle sprains)
(discussing cessation of problem solving treatment 
sessions) Did I drop out? No, I didn’t dropout. I became 
busy and I figured I started missing calls.23 (Female, no 
age details, cancer and depression)
DIsCussIOn
Principal findings
Our meta-ethnographic synthesis sought to explore 
factors that influence non-retention within clinical trial 
contexts. We identified 11 studies (reporting qualitative 
data from 13 trials) that explored participant-reported 
reasons for not completing any or some of the various 
trial processes (after initially consenting to take part). 
What emerged from our analysis was the importance 
of trial participants’ perceptions about the personal 
compatibility of key aspects of the trial with their 
personal beliefs, preferences, capabilities or life circum-
stances. These factors related to their own health state, 
preferences for how they wanted to receive care, their 
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individual capabilities, beliefs about or experiences of 
trial medication and also considerations around the 
extent to which trial participation could be appropriately 
accommodated or not into their broader lives (conceptu-
ally illustrated in online supplementary S3 figure). Our 
synthesis has also highlighted that people’s reasoning 
around dropping out of a trial can be described as being 
more or less ‘active’ in nature, with some people in our 
synthesis not even realising that they were being consid-
ered by the researchers as trial ‘drop outs’.23 All these 
factors raise important issues around the extent to which 
initial decisions to participate were fully informed and 
illustrate the importance for trial recruiters of ensuring 
that prospective participants are made aware of what the 
trial will entail and also what will be expected of them in 
terms of full participation.
Quantitative surveys have tended to investigate non-re-
tention in the context of non-response to follow-up 
questionnaires. These studies have identified either partic-
ipant characteristics or trial processes as being potential 
predictors of trial retention.9–11 While these studies have 
a place, it is arguably difficult to influence some of these 
previously identified factors influencing retention as they 
may not be modifiable, for example, age or study dura-
tion. Our synthesis of more in-depth qualitative data has 
usefully built on these findings and has enabled a more 
nuanced understanding of key issues of relevance (which 
are potentially modifiable) relating to non-adherence to 
interventions and non-return of follow-up questionnaires. 
Participant characteristics as well as trial processes are of 
importance but we have also demonstrated that there 
can be a complex inter-relationship between the two. For 
example, a perception that the nature of the intervention 
negatively affects one’s mental health can be of impor-
tance as can perceptions about the nature of the inter-
vention in relation to perceptions of self or in relation to 
personal preferences for care and support. Furthermore, 
the compatibility or otherwise of various trial processes 
with individual capabilities can have implications for 
retention. Reasons given for not completing various trial 
processes were not necessarily mutually exclusive, but 
were rather a synergistic combination of factors that could 
apparently work towards trial non-retention. Our findings 
also highlight that some participants’ behaviour around 
leaving a trial could be described as being more or less 
‘active’ in nature (eg, stopping trial medication because 
of a concern around side effects (active) versus simply not 
remembering or being too busy to return a questionnaire 
(passive)). This is an important finding and one that has 
not been given due consideration in previous literature 
to date. People’s views and life situations can change over 
time, all having the potential to impact on their retention 
within a trial. Furthermore, different types of trials are 
likely to present particular challenges in terms of their 
potential for non-retention. It could also be that certain 
types of reasoning might be more or less modifiable and 
easier to address particularly if they can be anticipated 
upfront during the trial design stage.
A recent study exploring reasons why people declined 
trial participation at the consent to recruitment stage 
has found that most declined at the outset because they 
judged themselves ineligible or not in need of the specific 
trial therapy in question.34 The study authors suggest that 
to improve recruitment to trials the most successful inter-
ventions are likely to be the ones that focus on patients’ 
assessments of their own eligibility and their potential to 
benefit from the trial treatment, rather than reducing trial 
burden per se. In our synthesis, we found that perceptions 
around eligibility and assessments regarding potential to 
benefit from the trial treatment were also considerations 
for people who had initially decided to join but who 
had subsequently ceased to engage. For example, this 
included those who felt that they had recovered such they 
did not need to engage further21–23 25 and those who felt 
they could manage sufficiently well without engaging with 
the intervention.21 28 29 However, in the context of non-re-
tention, it is worth considering issues around trial burden 
(eg, interventions that might be perceived to be too tech-
nical or too demanding given a person’s health state) as 
well as issues around preference for particular styles of 
care and support and acknowledging that the specific 
intervention and, or, the ways outcomes are assessed has 
to be compatible within the context of trial participants’ 
broader lives. In other words, issues around reducing trial 
burden is of importance, both in terms of the intervention 
itself and also the ways that follow-up data are collected.
We know from previous syntheses of qualitative 
studies focusing on trial recruitment that people often 
choose to enter into trials in the hope of gaining some 
help for themselves from the intervention (even if they 
also state they are doing so for altruistic reasons, ie, to 
benefit research more generally), so-called ‘conditional 
altruism’.7 Some participants in our synthesis described 
perceptions around feeling too ill to continue taking part 
or feeling suitably better such that trial engagement was 
no longer warranted.21–25 This perception of improvement 
in health would appear to resonate with the concept of 
conditional altruism in the sense that people might cease 
participation if they perceive their condition improves or 
conversely deteriorates, such that in effect their benefit 
for self has been realised and their continued participa-
tion is no longer warranted. Our finding here is perhaps 
exaggerated in trials with a mental health context (which 
applied to 6 of the 13 included trials), where diagnoses 
can adversely affect people’s ability and inclination to 
initially take part in research.34–36 We have shown that 
this issue also has relevance for retention in such trials 
as people’s health states can be particularly vulnerable to 
fluctuation.34 A recent meta-synthesis of factors affecting 
recruitment to depression trials37 indicated that decisions 
can depend on issues relating to: perceptions of health at 
the time of invite; attitudes towards the research and trial 
interventions and the demands of the trial. Our synthesis 
has shown that some of this reasoning might also have 
the potential to impact on non-retention in those who are 
successfully recruited. Furthermore, previous research 
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has suggested that the therapeutic alliance can have an 
impact on adherence to treatment.38 Within the papers 
included in our synthesis, this was not something that was 
discussed per se. However, as one of our key themes illus-
trate, some decisions to discontinue trial participation 
appeared to relate to the fit of aspects of the intervention 
with preferences for how participants wanted to receive 
care and support. Within this, some trial non-retainers 
stated that they had wanted more face-to-face personal 
contact with, for example, a therapist. This comparable 
finding could suggest that the underlying beliefs, pref-
erences and expectations about trial participation are 
not explored and unpacked fully during trial consenting 
discussions.
strengths and limitations
We recognise that different review teams may interpret 
qualitative data in slightly different ways due to pre-ex-
isting world views or expertise across research areas. 
However, a strength of undertaking a meta-ethnographic 
synthesis of findings from studies providing qualitative 
data on factors influencing non-retention within clinical 
trials is that it has allowed us to gain important new shared 
insights into factors that seem to affect retention across a 
range of trial contexts—to our knowledge, this is the first 
study to have synthesised these primary studies in this way. 
Through synthesising, we have been able to pull insights 
from across studies, providing learning from their collec-
tive contributions. However, our systematic search iden-
tified only 11 eligible papers reporting findings across 
13 trials, 5 of which had a mental health context and 
all of which were conducted in high-income countries. 
This in part perhaps reflects the difficulties researchers 
face in gaining access to the views of those who disen-
gage with research. Furthermore, unlike surgical trials, 
all the included papers incorporated within their trials, 
interventions that participants could choose to discon-
tinue engaging with (eg, taking drugs; stopping CBT, 
etc). While qualitative research does not usually intend to 
be generalisable, it is nevertheless important to consider 
the transferability of our findings to other clinical trial 
contexts and settings and one could argue that partici-
pants within mental health trials, surgical trials or trials 
that involve surrogate/proxy consent including those 
involving children27 might face very different issues and 
challenges regarding retention. Although we were reas-
sured that the key themes we identified had resonance 
across the included papers to a greater or lesser extent 
and so are likely to be important considerations within a 
range of clinical trial contexts, some influences on trial 
non-retention are likely to be more trial specific than 
others (eg, concerns about trial medication).
We carried out a quality assessment of the 11 included 
papers (see online supplementary S1 CASP Checklist). 
Although all papers had study aims that were amenable 
to investigation via qualitative means and all included 
qualitative data, some were deemed richer than others in 
terms of data and insights (ie, first-order and second-order 
constructs). Arguably, this made undertaking a meta-eth-
nography in this context quite challenging as the number 
of studies and volume and/or quality of available data 
can affect depth of analysis. For example, one paper only 
reported qualitative data from open-ended questionnaire 
response options,22 and two were deemed less useful in 
terms of presenting only very limited qualitative data (both 
first-order and second-order constructs).22,23 Neverthe-
less, we did feel that they provided some helpful insights 
that usefully built on the findings of the other papers. 
Furthermore, despite some variation in the overall level 
of quality, due to the small number of included studies 
we felt it was more important to retain any relevant find-
ings rather than disregard based on study quality. In 
doing so, we would argue that all 11 papers contributed 
useful elements to the collective whole and enabled us 
to develop our line of argument in terms of the issues of 
importance regarding trial non-retention.
Practice implications
The way in which a trial is presented to individuals needs 
to take account of the influencing factors we have identi-
fied in this synthesis. While not all the factors we identified 
are modifiable, there influence needs to be recognised. 
We would argue that trialists need to think carefully about 
how the design of their trial might contribute to non-re-
tention and that there is potential to modify trial design 
to improve retention.
To improve retention in clinical trials, researchers 
should work to reduce the burden on trial participants 
both through the design of the intervention itself as well 
as through simplified data collection processes. Providing 
more detail on the nature of the trial interventions and 
what can be expected by ‘participation’ (ie, when and 
how data will be collected) at the consenting stage may 
prove helpful in order to manage expectations.
Some people in our synthesis appeared to be unaware 
that they were being considered as trial non-retainers by 
the study researchers. This raises the question of partici-
pants’ understanding of the importance of remaining in 
a trial for its duration (ie, completing the intervention 
and the outcome assessments) and its implications for the 
study in question. This finding is supported by a recent 
study of patient information documentation from UK 
NIHR funded trials that has highlighted that withdrawal 
and retention are poorly described and that statements 
about the value of retention are infrequent.39 If trialists 
want to improve retention to clinical trials then there is 
an argument for giving the importance of completing the 
trial more prominence in patient information materials 
(and also during any trial recruitment discussions).
Our synthesis also potentially highlights the issue of 
people’s awareness or lack thereof of what the trial inter-
ventions would entail. If trialists want to improve reten-
tion then this suggests an argument for also providing 
more detail on the nature of the trial interventions at 
the consenting stage in order to manage expectations. 
We know from previous literature that patient/public 
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involvement at the front end of trial design tends to be 
extremely limited if indeed it happens at all.40 41 Given 
some of the key factors we found as being influential for 
non-retention, one could speculate that some early and 
meaningful patient/public involvement would be partic-
ularly useful (eg, for ensuring that aspects of the trial are 
user-friendly and as compatible as possible with the target 
population’s likely preferences and capabilities).
Implications for research
A Cochrane review investigating interventions to improve 
retention in trials has highlighted that most strategies 
to improve retention have focused on trying to improve 
follow-up questionnaire response.42 Of these interven-
tions, only monetary incentives have been shown to 
have a significant effect on return of questionnaires and 
the review highlighted that very few studies included 
trial participants in their design or development.42 Our 
synthesis has demonstrated that there may be a range of 
issues relevant to trial participants that influence non-re-
tention, which may not be amenable to modification by 
‘incentives’ or other interventions that fail to consider 
participants during development.
As mentioned previously, qualitative methods to improve 
recruitment to trials is now recognised as a well-established 
methodology built into the design and delivery of large 
publicly funded clinical trials. The Qunitet Recruitment 
Intervention (QRI) is gathering momentum across a range 
of trials and Clinical Trials Units as a mechanism to unpack 
many of the nuances around how participants are recruited 
to RCTs.43 Many of the approaches in the QRI are directly 
transferable to questions about retention. For example, how 
it is discussed in consultations and trial paperwork, what 
do stakeholders (trial participants and trial staff) report as 
the barriers and facilitators to retention, and work in this 
area could prove fruitful for minimising non-retention in 
ongoing RCTs. However, despite there being a clear need 
for more research in the context of trial retention, we 
also recognise the inherent challenges for researchers in 
obtaining the necessary ethical approvals for this type of 
research (particularly as current recruitment materials for 
trial participants tend to emphasise prospective participants’ 
right to withdraw without given any reasons, etc). Therefore, 
development of shareable resources to facilitate regulatory 
approvals may be an important contribution for the trials 
methodology community.
Finally, given that synthesis was based on a sparse data 
set, with 5 of the 11 included studies focused on qualitative 
research within mental health trials, there is certainly scope 
for more good quality, rigorous primary studies exploring 
the barriers and enablers to trial retention from a partici-
pant’s perspective across a range of clinical specialties and 
trial design types. Interestingly, our search did not identify 
any studies that had explored reasons for trial participants’ 
non-attendance at trial follow-up visits. Ideally, future studies 
should consider and explore all aspects of trial process rele-
vant for retention, including completion and return of data 
(and its mode of delivery or collection), and attendance at 
follow-up visits. A recent prioritisation exercise for research 
into trial retention has now identified the top 10 unanswered 
questions for trial retention.44 Many of these top 10 ques-
tions lend themselves well to enquiry by qualitative research 
methods and priorities should be focused here.
COnClusIOns
Our systematic literature search and synthesis has high-
lighted that there is very little published qualitative literature 
exploring participant-reported reasons for non-retention in 
clinical trials. Researchers have already called for ‘a science 
of recruitment’ in recognition that recruiting for science 
(eg, trials) is not currently underpinned by an evidence base 
around the factors which might have the potential to impact 
on recruitment.1 This is undoubtedly important but we 
would also argue that we need to develop a parallel focus on 
‘a science of retention’ if we are to start to be able to tackle 
the very real issue of non-retention in clinical trials. Our 
qualitative synthesis (of a small set of studies) feeds into this 
relatively undeveloped science and has shed some important 
light on the factors that might influence non-retention in 
clinical trials—factors that have implications both for prac-
tice and for further research. Taken together, the findings 
presented here and the subsequent implications for practice 
and research highlight the critical need to plan for retention 
as much as for recruitment during trial design and not treat 
it like the overlooked trial conduct ‘Cinderella’.
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